Pheast Therapeutics

Home - Pheast

Redwood City, United States · Founded 2020 · $101.0M raised

Employees
11–50
Founded
2020
Business Model
B2B
Website
pheast.com
Total Funding
$101.0M
Last Round
$25.0M Series BApr 2022
Rounds
2

About

Pheast Therapeutics is a clinical-stage immuno-oncology company developing macrophage checkpoint inhibitors to activate the innate immune system against cancer. Building on Stanford discoveries that CD24 is a dont-eat-me signal used by tumors, the company is advancing PHST001, an anti-CD24 antibody, in a Phase 1 study of advanced solid tumors. Pheast also uses a discovery platform to find additional macrophage-targeted immunotherapies and combination strategies with existing anti-cancer treatments. The company is led by the scientists who made the foundational discoveries and is backed by investors including Catalio Capital Management and ARCH Venture Partners.

Summary

Pheast Therapeutics is a Biotech company based in Redwood City, United States, founded in 2020. It has raised $101.0M in total across 2 rounds, most recently a $25.0M Series B round in Apr 2022. Investors include ARCH Venture Partners, Catalio Capital Management and Alexandria Venture Investments.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AApr 2022
$76.0M

Sign up to see all 2 rounds

Series B through Series A — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Pheast Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/pheast-therapeutics"><img src="https://indexed.vc/api/badge/company/pheast-therapeutics" alt="Pheast Therapeutics on Indexed.vc" width="260" height="76" /></a>